This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results 2009-11-10 16:00 ET - News Release TORONTO, Nov. 10, 2009 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended September 30, 2009.
Selected Highlights
During the first quarter of fiscal 2010 and up to the date of this press release, the Company achieved the following significant milestones:
ELND005 (AZD-103) - Alzheimer's Disease:
. On July 13, 2009, Elan and Transition announced Phase I data
showing ELND005 (AZD-103) achieves desired concentrations in
brain tissue and cerebrospinal fluid when given orally.
Preclinical data also were presented showing that ELND005
(AZD-103) administration is associated with preservation of
choline acetyltransferase (ChAT), reflecting preservation of
nerve cells that are critical to memory function in the brain.
These results were presented at the 2009 Alzheimer's Association
International Conference on Alzheimer's Disease (ICAD 2009) in
Vienna, Austria.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. | 
Top
Print this Page